A case report of alloimmune hepatitis after direct-acting antiviral treatment in a liver transplant patient

Catherine Choi, Youssef Botros, Jamil Shah, Pei Xue, Anja Jones, Mark Galan, Raquel Olivo, Mumtaz Niazi, Flavio Paterno, James Guarrera, Nikolaos T. Pyrsopoulos

Research output: Contribution to journalArticlepeer-review

Abstract

Direct-acting antiviral (DAA) therapy is often well-tolerated, and adverse events from DAA therapy are uncommon. We report a case of a woman who underwent orthotopic liver transplant for chronic hepatitis C infection and later developed alloimmune hepatitis shortly after starting DAA therapy for recurrent hepatitis C infection. The patient developed acute alloimmune hepatitis approximately 2 weeks after starting treatment with sofosbuvir, velpatasvir, and voxilaprevir. This case report proposes a dysregulation of immune surveillance due to the DAA stimulation of host immunity and rapid elimination of hepatitis C viral load as a precipitating factor for the alloimmune process, leading to alloimmune hepatitis in a post-transplant patient who starts on DAA.

Original languageEnglish (US)
Pages (from-to)459-462
Number of pages4
JournalJournal of Clinical and Translational Hepatology
Volume8
Issue number4
DOIs
StatePublished - 2020

All Science Journal Classification (ASJC) codes

  • Hepatology

Keywords

  • Autoimmune hepatitis
  • Hepatitis C
  • Liver transplant

Fingerprint

Dive into the research topics of 'A case report of alloimmune hepatitis after direct-acting antiviral treatment in a liver transplant patient'. Together they form a unique fingerprint.

Cite this